Oncology
Curated shortlist of Class A academic cancer centres delivering modern oncology care for international patients — including domestic PD-1 inhibitors, CAR-T, proton and heavy-ion therapy access.
These are the academic cancer centres most-used by international patients seeking modern oncology in China — chosen for procedure volume, multidisciplinary depth, access to NMPA-approved domestic immunotherapies (often unavailable or unaffordable elsewhere), and structured international patient services.
Flagship national cancer centre; broadest active clinical trial portfolio in China; multidisciplinary tumour board for solid and haematologic malignancies. Strong second-opinion programmes.
One of the largest comprehensive cancer centres in China by volume; deep specialty depth in breast, GI, and head-and-neck oncology; integrated with proton therapy referral pathway.
National flagship for nasopharyngeal carcinoma — highest-volume NPC programme globally and origin of toripalimab approval. Strong solid tumour multidisciplinary care.
Globally-influential haematology programme — pioneer of CAR-T cell therapy in China; broadest experience with relapsed/refractory lymphoma and multiple myeloma.
One of few centres globally with both proton and carbon-ion therapy — critical for selected radioresistant tumours, paediatric cases, and re-irradiation.
Major academic cancer centre in northern China; deep gastric and lung cancer programmes; rapidly expanding international patient services.
Specialised lymphoma / multiple myeloma CAR-T centre with high volumes and structured international referral.
For complex oncology cases, a remote second opinion from one of these centres is the appropriate first step — see our second-opinion workflow guide.
China has approved four major domestic PD-1 inhibitors with strong clinical evidence in multiple tumour types. The cost gap with Keytruda is enormous — but so are the indication differences. Here is the careful comparison.
OncologyChina has emerged as a global leader in CAR-T cell therapy delivery and clinical research. Here is the current state — approved indications, leading centres, costs, and the realistic outcomes data.
OncologyChina is one of the few countries with operational heavy-ion therapy alongside proton therapy. Here is how the three modalities differ, where each fits clinically, and what they cost.
Medical TourismBefore flying, get a written second opinion from a senior Chinese specialist via telehealth. Here is the standard 7-day workflow, what's included, and what it costs.
Free 30-minute consult to discuss your case and which hospital pathway fits best.
Book free consult